1,032 results on '"Giobbie‐Hurder, Anita"'
Search Results
152. Supplementary Figure 2 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
153. Data from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
154. Supplemental Tables from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
155. Supplemental Figure Legends from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
156. Supplementary Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
157. Supplementary Table 1 and Supplementary figure legends from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
158. Supplementary Figure 2 from The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
159. Supplementary Figure 3 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
160. Supplemental Table 1 from Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
161. Supplementary Figure 3 from The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
162. Supplementary Figure 1 from Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors
163. Supplementary Figure 1 from The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
164. Supplementary Figure Legend from The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
165. Data from Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
166. YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma
167. An immunogenic personal neoantigen vaccine for patients with melanoma
168. Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
169. Targeting TBK1 to overcome resistance to cancer immunotherapy
170. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
171. Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma
172. Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes
173. Reply to: “Comment on ‘Bullous pemphigoid after anti–PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes’”
174. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course
175. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
176. A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
177. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
178. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
179. Acupuncture for hot flashes in hormone receptor-positive breast cancer, a coordinated multinational study: Rationale and design of the study protocol
180. S65 Distinct Imaging Patterns of Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
181. Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study
182. Psychosexual Functioning and Body Image Following a Diagnosis of Ductal Carcinoma In Situ
183. A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
184. Cutaneous Langerhans cell histiocytosis in adults: A retrospective cohort study of adult patients presenting to a single academic cancer center between 2003 and 2017
185. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
186. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome
187. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer
188. Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.
189. Evaluation of the use of COVID-19 vaccines in patients treated with immunotherapy.
190. Acupuncture for hot flashes in hormone receptor-positive breast cancer, a pooled analysis of individual patient data from parallel randomized trials.
191. Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid
192. Cancer Survivors' Perspectives of Virtual Yoga for Chronic Chemotherapy-Induced Peripheral Neuropathy Pain During the COVID-19 Pandemic
193. Exploring Daily Salivary Cortisol Patterns as Biomarkers of Chronic Chemotherapy-Induced Peripheral Neuropathy Pain
194. Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study
195. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors
196. Impact of a Mixed Strength and Endurance Exercise Intervention on Levels of Adiponectin, High Molecular Weight Adiponectin and Leptin in Breast Cancer Survivors
197. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
198. Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
199. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
200. Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.